<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630198</url>
  </required_header>
  <id_info>
    <org_study_id>181119</org_study_id>
    <nct_id>NCT03630198</nct_id>
  </id_info>
  <brief_title>Pain Outcomes Following Intralesional Corticosteroid Injections</brief_title>
  <official_title>The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corticosteroid therapy, including intralesional and topical applications, has many
      indications within the fields of Dermatology, Plastic Surgery, and Orthopedics. However,
      these injections can be quite painful, which leads many patients to discontinue treatment.

      Often, the injection involves a mixture of local anesthetic and corticosteroids despite a
      lack of evidence that the use of lidocaine improves pain. Due to the acidic pH, the lidocaine
      component of the injection can actually cause a significant burning sensation during the
      procedure. Lidocaine does not have anti-inflammatory properties and does not treat the
      underlying pathology. By including another medication, lidocaine also adds cost and risk to
      the procedure.

      The purpose of this study is to see if removing lidocaine from intralesional injections
      decreases the pain of injection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain outcome: visual analog scale</measure>
    <time_frame>Assessed 1 minute after the injection (in clinic)</time_frame>
    <description>Assessed using the visual analog scale (0-10 scale). Zero indicates no pain, 10 indicates worst pain ever.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Outcome: visual analog scale</measure>
    <time_frame>Assessed 6 hours after injection (by phone), and 24 hours after injection (by phone)</time_frame>
    <description>Assessed using the visual analog scale (0-10 scale). Zero indicates no pain, 10 indicates worst pain ever.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Keloid</condition>
  <condition>Alopecia Areata</condition>
  <condition>Acne</condition>
  <condition>Hypertrophic Scar</condition>
  <condition>Epidermal Inclusion Cyst</condition>
  <condition>Frontal Fibrosing Alopecia</condition>
  <condition>Lichen Plano-Pilaris</condition>
  <condition>Keratoacanthoma</condition>
  <condition>Plaque Psoriasis</condition>
  <condition>Lichen Simplex Chronicus</condition>
  <condition>Prurigo Nodularis</condition>
  <condition>Nummular Eczema</condition>
  <condition>Granuloma Annulare</condition>
  <condition>Morphea</condition>
  <condition>Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Corticosteroid with lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will include an injection mixture of corticosteroid and lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid with normal saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include a mixture of corticosteroid and normal saline. The purpose of normal saline is to keep the volume and concentration similar when compared to the injections containing lidocaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid with lidocaine</intervention_name>
    <description>Intralesional corticosteroid injection</description>
    <arm_group_label>Corticosteroid with lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid with normal saline</intervention_name>
    <description>Intralesional corticosteroid injection</description>
    <arm_group_label>Corticosteroid with normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;12 years old presenting with an indication for intralesional steroid injection

        Exclusion Criteria:

          -  Unconsentable

          -  Not a candidate for corticosteroid injection

          -  Contraindication to lidocaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Drolet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian C Drolet, MD</last_name>
    <phone>(615) 322-7311</phone>
    <email>brian.c.drolet@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian C Drolet, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Brian Drolet</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>corticosteroid</keyword>
  <keyword>local anesthetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermal Cyst</mesh_term>
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
    <mesh_term>Prurigo</mesh_term>
    <mesh_term>Granuloma Annulare</mesh_term>
    <mesh_term>Neurodermatitis</mesh_term>
    <mesh_term>Keratoacanthoma</mesh_term>
    <mesh_term>Cicatrix, Hypertrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

